Aimmune Therapeutics' (AIMT) top-line results from the Palisade study suggest that AR101 could be an effective treatment for the desensitization of peanut allergy patients to peanut protein, Deutsche Bank analyst Andrew Peters tells investors in a research note. The analyst, however, believes AR101 "continues to be a potentially challenging therapy from a tolerability and safety perspective" with 20.4% of patients discontinuing therapy for all causes. AR101's profile is "far from suggestive of an all-encompassing option for patients," leaving "meaningful opportunity" for other agents, Peters contends. As such, he sees room for both AR101 and DBV Technologies' (DBVT) Viaskin Peanut. The analyst keeps a Buy rating on DBV shares with a $30 price target.